Telavancin

Next Previous
Drug Profile

Telavancin

Alternative Names: Arbelic; TD-6424; Telavancin hydrochloride; Vibativ

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance
  • Developer Clinigen; Innoviva; PENDOPHARM; Theravance Biopharma; University of Illinois at Chicago
  • Class Aminoglycosides; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell membrane permeability enhancers; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Skin and soft tissue infections

Highest Development Phases

  • Marketed Nosocomial pneumonia; Skin and soft tissue infections
  • Registered Bacteraemia
  • Phase III Osteomyelitis
  • Phase I Bacterial infections
  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 31 Dec 2017 Theravance Biopharma terminates a phase III trial in Bacteraemia in USA before December 2017 (NCT02208063)
  • 05 Jun 2017 Antimicrobial data from preclinical studies in Bacterial infections presented at the annual meeting of the American Society for Microbiology (ASM-2017)
  • 20 Apr 2017 Telavancin is available for licensing in (excluding USA) as of 19 Apr 2017. www.theravance.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top